Small cap Tex Mex or Mexican restaurant stock El Pollo LoCo Holdings Inc (NASDAQ: LOCO) reported�Q2 2017 earnings after the market closed Thursday.
Total revenue increased 8.3% to $105.6 million as system-wide comparable restaurant sales increased 2.9% -�including a 2.4% increase for company-operated restaurants and a 3.2% increase for franchised restaurants. The growth in company-operated restaurant revenue was largely driven by the 24 new restaurants opened during and subsequent to the second quarter of 2016. Comparable company-operated restaurant sales increased 2.4%, driven by a 0.5% increase in transactions and a 1.9% increase in average check. Net income was $7.8 million versus net income of $7.3 million. The CEO commented:
"During the second quarter we achieved solid results, including system-wide comparable store sales growth of 2.9% and a return to positive transaction growth.� Our core business continues to perform well, driven by our strategy to highlight our authentic brand, our differentiated offerings, and our QSR+ positioning.� Additionally we made progress against new technology initiatives focused on driving convenience and loyalty, rolling out delivery and launching our all-new Loco Rewards loyalty program."
Best Small Cap Stocks To Own Right Now: Argo Group International Holdings Ltd.(AGII)
Advisors' Opinion:- [By Stephan Byrd]
Argo Group (NASDAQ: AGII) and Stewart Information Services (NYSE:STC) are both small-cap finance companies, but which is the better business? We will compare the two companies based on the strength of their valuation, risk, earnings, dividends, institutional ownership, profitability and analyst recommendations.
- [By Max Byerly]
Lord Abbett & CO. LLC purchased a new position in shares of Argo Group (NASDAQ:AGII) in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 840,251 shares of the insurance provider’s stock, valued at approximately $48,230,000. Lord Abbett & CO. LLC owned approximately 2.49% of Argo Group as of its most recent filing with the SEC.
- [By Joseph Griffin]
Barclays PLC raised its stake in Argo Group (NASDAQ:AGII) by 25.3% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 8,691 shares of the insurance provider’s stock after acquiring an additional 1,754 shares during the period. Barclays PLC’s holdings in Argo Group were worth $499,000 as of its most recent SEC filing.
Best Small Cap Stocks To Own Right Now: Galmed Pharmaceuticals Ltd.(GLMD)
Advisors' Opinion:- [By Jon C. Ogg]
Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) was started as Outperform with a $26 price target at Raymond James on July 20, and that was versus a previous $15.02 closing price. A week earlier, on�June 13, Stifel Nicolaus initiated Galmed with a Buy rating and issued a $35 price target that would imply more than 100% upside. Galmed has been quite volatile as its 52-week range is listed at $3.61 to $27.06. It had a $322 million market cap as of�Friday. Galmed, which focuses on diseases and issues targeting the liver, closed at $15.00�on Friday. Its lead product candidate is RA101495, an injection into the tissue under the skin that has completed Phase II clinical trial for the treatment of paroxysmal nocturnal hemoglobinuria.
- [By Keith Speights]
That's exactly what happened this week with three small biotech stocks. Galmed Pharmaceuticals (NASDAQ:GLMD), Galectin Therapeutics (NASDAQ:GALT), and Eloxx Pharmaceuticals (NASDAQ:ELOX) soared on news that excited investors. Here's what drove these stocks higher -- and whether or not they're smart picks for investors now.
- [By George Budwell]
Over the last two weeks, shares of�Madrigal Pharmaceuticals (NASDAQ:MDGL), Galmed Pharmaceuticals (NASDAQ:GLMD), and Viking Therapeutics (NASDAQ:VKTX) have more than doubled in value. The reason?
- [By Shane Hupp]
Here are some of the media stories that may have effected Accern’s rankings:
Get Galmed Pharmaceuticals alerts: Galmed Pharmaceuticals’ (GLMD) CEO Allen Baharaff on Q1 2018 Results – Earnings Call Transcript (seekingalpha.com) What You Must Know About Galmed Pharmaceuticals Ltd��s (NASDAQ:GLMD) Market Risks (finance.yahoo.com) Obeticholic Acid Market Analysis, Recent Trends and Regional Growth Forecast by Types, Applications and Economic … (theexpertconsulting.com) oholic Steatohepatitis (NASH) Market 2023: Know Marketing Channel Future Trend, Growth and Price with Future … (theexpertconsulting.com) Umbilical Cord Blood May Offer Early FH Diagnosis (medscape.com)A number of equities analysts have recently commented on GLMD shares. ValuEngine lowered shares of Galmed Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, February 14th. Maxim Group set a $14.00 price target on shares of Galmed Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, May 9th. Finally, HC Wainwright lifted their price target on shares of Galmed Pharmaceuticals from $18.00 to $24.00 and gave the stock a “buy” rating in a report on Monday, February 12th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $20.40.
- [By Sean Williams]
Similar strength was seen from microcap Galmed Pharmaceuticals (NASDAQ:GLMD), which rose by more than 150% during a single trading session two weeks ago despite mixed results. The move followed the release of phase 2b data from its 52-week Arrest study for NASH drug hopeful Aramchol. In that trial, a statistically significant reduction in liver fat was noted with one of the two doses (the 400 mg dose). However, the 600 mg dose led to a statistically significant improvement in overall NASH resolution (19.2% vs. 7.5%) and NASH resolution without worsening of fibrosis (16.7% vs. 5%) relative to the placebo.�
- [By George Budwell]
Shares of the clinical-stage biotech Galmed Pharmaceuticals (NASDAQ:GLMD) are on absolute fire this morning, thanks to a positive midstage trial readout for its experimental nonalcoholic steatohepatitis (NASH) drug Aramchol. Specifically, the company reported that patients receiving the 400 mg dose of Aramchol exhibited a significant reduction in liver fat over the study period compared to those taking a placebo. Curiously, though, patients receiving the higher dose of 600 mg apparently only showed a statistically significant drop in liver fat relative to placebo patients in a post-hoc analysis, according to the press release.�
Best Small Cap Stocks To Own Right Now: Insys Therapeutics, Inc.(INSY)
Advisors' Opinion:- [By Keith Speights]
The Intelligent Investor was written in 1949, but it's still as relevant nearly 70 years later as it was back then. Benjamin Graham was right about how crazy the market can be at times. I think the experiences of two very different biotech stocks this week -- Celgene (NASDAQ:CELG) and Insys Therapeutics (NASDAQ:INSY)�-- prove the point.
- [By Max Byerly]
Get a free copy of the Zacks research report on Insys Therapeutics (INSY)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Keith Speights]
What about�Insys Pharmaceuticals (NASDAQ:INSY)? The biotech's lead product is an opioid drug, but it also has an approved cannabinoid drug on the market for treating�anorexia in people with AIDS who have lost weight, and chemotherapy-induced nausea and vomiting. Insys�has a couple of experimental pain drugs in its pipeline -- but none of them are cannabinoids. The company's lead cannabinoid candidate targets childhood absence epilepsy, infantile spasms, genetic disorder Prader-Willi syndrome -- but not pain.
- [By Casey Wilson]
Others, like cannabis biotech firm Insys Therapeutics Inc. (Nasdaq: INSY), are direct plays in marijuana businesses that offer investors the opportunity for incredibly fast gains.
- [By Keith Speights]
Insys Pharmaceuticals (NASDAQ:INSY) and Cara Therapeutics (NASDAQ:CARA) fall into the third category. However, the designations of both Insys and Cara as marijuana�stocks warrant an asterisk. Insys' cannabinoid drug Syndros is based on a synthetic form of THC, the primary psychoactive chemical in marijuana. Cara has a cannabinoid receptor agonist, CR701, in preclinical development.
No comments:
Post a Comment